MedPath

A retrospective observational study of investigating the real world data of post-treatment after drug-induced lung injury by osimertinib and the safety and efficacy of EGFR-TKI re-challenge

Not Applicable
Recruiting
Conditions
on small cell lung cancer
Registration Number
JPRN-UMIN000044854
Lead Sponsor
Thoracic Oncology Research Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
250
Inclusion Criteria

Not provided

Exclusion Criteria

Patients participating in studies aimed at similar analysis of treatment after Osimertinib

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath